Of note, clinically relevant targets such as BRAF and NRAS have comparable incidences (53–58% for BRAF and 23–28% for NRAS, respectively) thus suggesting the value of larger scale sequencing in the melanoma context. The gene discussed is NRAS; the disease is melanoma.